Lipidoid mRNA nanoparticles for myocardial delivery in rodents
Name
nihms882725.pdf
Description
Accepted version
Size
2.19 MB
Format
Adobe PDF
Checksum (MD5)
59fab1bb0329b7c9ecd4e40f26373557
Author(s) • • •
Turnbull, IC
Eltoukhy, AA
Anderson, DG
Costa, KD
Date Issued
January 1, 2017
Journal
Methods Mol Biol
Publisher
Springer New York
Citation
Turnbull, I. C., et al. "Lipidoid Mrna Nanoparticles for Myocardial Delivery in Rodents." Methods Mol Biol 1521 (2017): 153-66.
Version
Author's final manuscript
Abstract
© Springer Science+Business Media New York 2017. An area of active research in the field of cardiac gene therapy aims to achieve high transfection efficiency without eliciting immune or inflammatory reactions. Nanomedicine offers an attractive alternative to traditional viral delivery vehicles because nanoparticle technology can enable safer and more controlled delivery of therapeutic agents. Here we describe the use of lipidoid nanoparticles for delivery of modified mRNA (modRNA) to the myocardium in vivo, with a focus on rodent models that represent a first step toward preclinical studies. Three major procedures are discussed in this chapter: (1) preparation of lipid modRNA nanoparticles, (2) intramyocardial delivery of the lipid modRNA nanoparticles by direct injection with an open chest technique in rats, and (3) intracoronary delivery of the lipid modRNA nanoparticles with open chest and temporary aortic cross clamping in rats.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
10.1007/978-1-4939-6588-5_10
https://doi.org/10.1007/978-1-4939-6588-5_10